real peptides FAQ

DSIP is not FDA-approved for any indication, meaning legal access is restricted to registered research institutions and clinical trials. Compounded versions marketed online lack purity verification, dosing standardisation, or evidence of bioequivalence to the peptide formulations used in published studies. For shift workers seeking circadian support, melatonin (0.5–3 mg taken 5–7 hours before desired sleep onset) and light therapy upon waking are evidence-based alternatives with established safety profiles.

This is the expected outcome. The one-week mark falls within the immune initiation phase, where molecular-level changes are occurring but clinical endpoints remain undetectable. Continue the dosing protocol as planned and evaluate at the 14-day and 28-day marks, which align with collagen deposition and re-epithelialisation timelines respectively. The absence of visible change at seven days does not indicate peptide failure unless laboratory markers (neutrophil counts, cytokine levels) also remain unchanged, which would suggest a formulation or storage issue.

NAD+ supplementation addresses a different mechanism than varenicline (partial nAChR agonist) or bupropion (dopamine/norepinephrine reuptake inhibitor), making it a plausible adjunct for individuals who didn't respond to first-line therapies. However, 'didn't work' often reflects issues beyond pharmacology. Insufficient behavioural support, environmental triggers, or co-occurring mental health conditions that require integrated treatment. NAD+ won't override those factors. If previous attempts failed due to intolerable side effects rather than lack of efficacy, NAD+ precursors have a favourable safety profile and may be worth exploring under medical supervision.

Combining NR with resveratrol or pterostilbene (direct SIRT1 activators) produces synergistic effects—NAD+ provides the cofactor while polyphenols lower the activation threshold. A 2021 trial combining 500mg NR with 150mg pterostilbene showed 67% greater SIRT1 activity than NR alone. Combining NR and NMN provides no additional benefit since both converge on the same biosynthetic pathway; use one precursor at optimal dose rather than splitting between two.

Begin with an oral NAD+ precursor (300–500mg NR or NMN daily) at least 7 days before your planned quit date if possible. NAD+ tissue repletion isn't instantaneous. Baseline levels take 10–14 days to normalise, and neurotransmitter pathway recovery lags behind biochemical restoration. Starting the day you quit means you're navigating peak withdrawal severity (days 3–7) before NAD+ levels have meaningfully improved. Pair supplementation with behavioural support and consider combining with FDA-approved cessation aids rather than relying on NAD+ alone.

Possibly, but the mechanism depends on whether your low sperm count is driven by central (hypothalamic/pituitary) suppression or testicular dysfunction. Men with normal testosterone but low sperm count often have partial FSH deficiency or suboptimal LH pulsatility that kisspeptin could correct. A 2021 Harvard study found that men with idiopathic oligozoospermia (unexplained low sperm count) still responded to kisspeptin with significant LH and FSH increases, suggesting latent HPG axis suppression even when baseline testosterone appears normal. If imaging or biopsy confirms primary testicular pathology (varicocele, atrophy, genetic abnormalities), kisspeptin won't address the root cause.

Circadian timing determines whether a sleep-modulating compound promotes or disrupts rhythm stability. DSIP administration in animal models showed phase-dependent effects. Dosing during the active phase (equivalent to human daytime for shift workers) produced minimal benefit, while dosing aligned with the animal's rest phase enhanced slow-wave sleep. Mistimed administration could theoretically worsen sleep fragmentation rather than consolidate it, though human data on this is absent.

Kisspeptin acts upstream of the point where clomiphene works. Clomiphene blocks estrogen receptors in the hypothalamus to disinhibit GnRH secretion, but if your GnRH neurons are poorly responsive to estrogen feedback in the first place, clomiphene won't help. Kisspeptin directly depolarises GnRH neurons via GPR54 activation, bypassing the estrogen receptor pathway entirely. Men who fail clomiphene therapy often have hypothalamic hyporesponsiveness rather than estrogen-mediated suppression. This is exactly the population where kisspeptin shows the most promise in research settings.

A viable Phase III trial for DSIP in shift work sleep disorder would need: (1) a standardised synthetic formulation with verified amino acid sequence and purity ≥98%, (2) a dosing protocol optimised for human circadian physiology (likely subcutaneous or intranasal to avoid first-pass metabolism), (3) polysomnographic endpoints measuring sleep architecture alongside subjective quality metrics, and (4) comparison against both placebo and an active comparator like melatonin or modafinil. Regulatory approval would also require safety data addressing long-term GABAergic modulation effects and circadian phase disruption risks.

If your goal includes preserving or restoring fertility, yes. Kisspeptin is categorically superior to testosterone replacement. TRT suppresses LH and FSH through negative feedback at the hypothalamus and pituitary, which shuts down intratesticular testosterone production and spermatogenesis within 8–12 weeks. Kisspeptin does the opposite: it stimulates your body to produce both testosterone and sperm by restoring the upstream GnRH pulse generator. The trade-off is administration complexity. Kisspeptin requires twice-daily subcutaneous injections and is not yet available as an approved pharmaceutical, whereas TRT is widely prescribed and typically administered once weekly.

Local tissue effects and systemic immune changes operate through partially independent pathways. LL-37 applied topically or injected locally drives keratinocyte migration, angiogenesis, and collagen synthesis through direct FPR2 signalling in dermal cells. These effects are anatomically localised and don't require systemic immune recalibration. Systemic immune marker improvements (circulating cytokines, peripheral Treg frequencies) depend on adequate peptide distribution beyond the local tissue site, which requires higher dosing or systemic administration routes. This dissociation between local and systemic outcomes is a known limitation of topical or subcutaneous LL-37 delivery. Intravenous or intraperitoneal routes show stronger systemic immune effects in animal models.

Latent intervention still produces measurable benefits. A 2023 study in adults aged 70–85 found that 12 months of NR supplementation improved cognitive processing speed by 9% and reduced inflammatory markers (IL-6, TNF-α) by 15–20% compared to placebo. Mitochondrial function improved but didn't reach levels seen in younger cohorts, suggesting earlier intervention preserves function more effectively than late-stage restoration. NAD+ sirtuins longevity genes activation works at any age but yields diminishing returns as baseline cellular damage accumulates.

The 25-minute plasma half-life limits single-dose efficacy to 4–6 hours; chronic stress paradigms spanning days or weeks require twice-daily administration to maintain steady-state anxiolytic effects. Alternatively, osmotic minipumps delivering continuous subcutaneous infusion (50–100 mcg/kg/day) sustain plasma levels and avoid handling stress from repeated injections. Our team has used this approach in chronic unpredictable stress models where daily injections themselves introduce confounding variables. Minipump delivery preserves anxiolytic effects while minimizing procedural stress artifacts.

Selank's multi-target mechanism means additive or synergistic effects are possible with other GABAergic, serotonergic, or anti-inflammatory compounds. Co-administration with benzodiazepines can potentiate sedation despite selank's non-sedating profile when used alone. The alpha-2/3 selectivity doesn't eliminate all downstream GABAergic effects. If combining agents, reduce doses proportionally and monitor for motor coordination deficits on rotarod or beam-walking tests. Drug interaction studies should include receptor occupancy assays or microdialysis to map overlapping mechanisms of action before behavioral testing begins.

Verify peptide reconstitution and storage conditions first. Selank degrades rapidly at temperatures above 4°C and loses potency within 72 hours if stored improperly post-reconstitution. Individual variability in stress susceptibility (approximately 30% of rodents show resilient phenotypes in social defeat paradigms) can also account for non-responders; stratify subjects by baseline anxiety behavior before treatment assignment. If variability persists, consider measuring plasma peptide levels via ELISA to rule out absorption or metabolism differences. Some rodent strains show altered peptide transport kinetics that affect bioavailability.

You're accepting the unknown. No published dataset tracks follistatin-344 safe long term use beyond 24 weeks in primates or 18 months in gene therapy patients with dystrophy. The theoretical concerns involve chronic suppression of TGF-beta signalling. Myostatin is part of a broader pathway that regulates tissue repair, fibrosis, and immune function. Disrupting one node in that network for years could theoretically cause downstream effects that 16-week rodent studies wouldn't detect. This isn't fearmongering. It's acknowledging what the data does and doesn't tell us.

Verify storage conditions first. SS-31 degrades rapidly above −20°C and in the presence of moisture. Lyophilised peptides should be stored in a desiccator or sealed with desiccant packets at −20°C or below. Once reconstituted in sterile water or buffer, SS-31 remains stable for 7–10 days at 2–8°C but degrades within 48 hours at room temperature. If storage conditions are correct and variability persists, request endotoxin re-testing. We've seen batches that passed initial LAL screening develop endotoxin contamination during shipping due to temperature excursions. Real Peptides includes cold packs in every shipment and tracks transit temperatures; if a package spent more than 24 hours above 25°C, we re-ship at no charge.

This is an expected vasodilatory response. VIP binds to VPAC receptors on vascular smooth muscle, triggering cyclic AMP-mediated relaxation and increased blood flow to peripheral tissues. Flushing typically appears 2–5 minutes post-injection, peaks at 10–15 minutes, and resolves within 30–45 minutes as plasma levels decline. If flushing is accompanied by dizziness, significant blood pressure drop, or difficulty breathing, the dose may be too high. Reduce by 25–30% for subsequent administrations and ensure adequate hydration before dosing.

Drop to 0.25–0.5mg and assess tolerance. Headaches during Dihexa use may reflect excessive acetylcholine demand. Rapid synaptogenesis increases cholinergic neuron activity, depleting acetylcholine precursors faster than dietary intake replenishes them. Supplementing with 300–500mg alpha-GPC or CDP-choline 30 minutes before Dihexa administration often resolves this. Brain fog, paradoxically, can result from over-activation of excitatory pathways without corresponding GABAergic balance. Some users report clarity improves when they pair Dihexa with magnesium threonate (2g daily) to support inhibitory signaling.

Discard it. DSIP stored above 8°C for more than 4 hours undergoes protein denaturation that cannot be reversed by returning it to refrigeration. The peptide may still appear clear and colourless, but its biological activity declines by an estimated 40–60% after 8 hours at room temperature. Using degraded peptide introduces uncontrolled variability into research outcomes and wastes the remaining doses in that vial.